All In Biotech

Drug Trial Radar · NCT06845306

The Use of Indocyanine Green Near-infrared Fluorescence for Bowel Perfusion Quantitative Assessment in Order to Prevent Anastomotic Leakage in Colorectal Surgery

Indocyanine Green Near-infrared Fluorescence Bowel Perfusion Quantitative Assessment to Prevent Anastomotic Leakage in Colorectal Surgery: a Multicentre, Randomised, Controlled Study

Last checked: Nov 19, 2026Latest source record: Feb 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 1,268 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,268

Planned (sponsor's estimate)

Start

Jun 1, 2025

Primary completion

Jul 1, 2026

Study completion Sep 1, 2026

Sponsor

Lead sponsor
Vadim KuznetsovResearch network
Sponsor type
Research network
First posted
Feb 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Anastomotic leakage (AL) is a serious complication after surgery for colon cancer, leading to a significant increase in mortality.Intraoperative fluorescence imaging using indocyanine green has proven to be a feasible and reproducible technique for real-time perfusion assessment. An increasing number of studies are being published on the use of indocyanine green (ICG) fluorescence imaging in colorectal cancer surgery, showing promising results. Therefore, we propose conducting a multicenter, randomized controlled trial to investigate the potential use of quantitative assessment of near-infrared fluorescence imaging with indocyanine green (ICG) to prevent anastomotic leaks during colorectal surgery.

Conditions

  • Colo-rectal Cancer
  • Colonic Neoplasms Malignant

Interventions

  • ICG-guided bowel perfusion assessmentDrug

    ICG will be injected before anastomosis is created, to quantitatively assess the perfusion status of the bowel.

  • Conventional Bowel Anastomosis groupOther

    conventional perfusion assessment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 30-days Anastomotic Leakage (AL) rateTime frame: 30-days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • BELOOSTROV Clinic of High Technologies

    Vsevolozhsk District, Leningradskaya Oblast', Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.